Bilateral hearing loss caused by anti-NMDA receptor encephalitis with teratoma: A case report

Abstract

Autoimmune encephalitis (AE) is an autoimmune disease in the central nervous system. Clinical manifestations include cognitive dysfunction, psychiatric-behavioral abnormalities, epilepsy, motor disorders, speech disorders, and memory impairment. Some patients do not have the characteristic clinical manifestations of the disease when they see a doctor, so they are easily diagnosed incorrectly. Autoimmune antibodies originate from genetic and acquired factors. Clinical data have found a correlation between ovarian teratoma and autoimmune encephalitis. This case reports a 34-year-old woman who was diagnosed with teratoma-associated anti-Nmethyl- D- aspartate receptor-mediated autoimmune encephalitis called anti-N-methyl-D-aspartate receptor encephalitis with bilateral hearing loss in 2021. Through this case report, clinicians will pay attention to autoimmune encephalitis and raise awareness of the specific clinical manifestations of autoimmune encephalitis, and focus on early identification. It means that clinicians should be familiar with the representative clinical manifestations of the disease.

Keywords

anti-NMDA receptor encephalitis / autoimmune encephalitis / epilepsy / hearing loss / teratoma

References

[1] Ly LT, Kreye J, Jurek B, et al. Affinities of human NMDA receptor autoantibodies: implications for disease mechanisms and clinical diagnostics. J Neurol. 2018;265(11):2625-2632.

[2] Lascano AM, Vargas MI, Lalive PH. Diagnostic tools for immune causes of encephalitis. Clin Microbiol Infect. 2019;25(4):431-436.

[3] StatPearls. Treasure Island (FL). StatPearls Publishing;2021.

[4] Tényi D, Szűcs A, Kovács N, Illés Z, Janszky J. Paraneoplastic anti-NMDA receptor encephalitis in 1830. Neurol Neuroimmunol Neuroinflam. 2020;7(6):e887.

[5] Dutra LA, Abrantes F, Toso FF, Pedroso JL, Barsottini OGP, Hoftberger R. Autoimmune encephalitis: a review of diagnosis and treatment. Arq Neuropsiquiatr. 2018;76(1):41-49.

[6] Tachibana N, Kinoshita M, Saito Y, Ikeda S. Identification of the N-Methyl-D-aspartate receptor (NMDAR)-related epitope, NR2B, in the normal human ovary: implication for the pathogenesis of anti-NMDAR encephalitis. Tohoku J Exp Med. 2013;230(1):13-16.

[7] Cheng H, Yang F, Zhang J, et al. Case report: anti-NMDA receptor encephalitis with bilateral hearing loss as the initial symptom. Front Neurol. 2021;12:648911.

[8] Vogrig A, Péricart S, Pinto AL, et al. Immunopathogenesis and proposed clinical score for identifying Kelch-Like protein-11 encephalitis. Brain Commun. 2021;3(3):fcab185.

[9] Dubey D, Wilson MR, Clarkson B, et al. Expanded clinical phenotype, oncological associations, and immunopathologic insights of paraneoplastic Kelch-like protein-11 encephalitis. JAMA Neurol. 2020;77(11):1420-1429.

[10] Mandel-Brehm C, Dubey D, Kryzer TJ, et al. Kelch-like protein 11 antibodies in seminoma-associated paraneoplastic encephalitis. N Engl J Med. 2019;381(1):47-54.

[11] Muri L, Le ND, Zemp J, Grandgirard D, Leib SL. Metformin mediates neuroprotection and attenuates hearing loss in experimental pneumococcal meningitis. J Neuroinflammation. 2019;16(1):156.

[12] Sechi E, Flanagan EP. Antibody-mediated autoimmune diseases of the CNS: challenges and approaches to diagnosis and management. Front Neurol. 2021;12:673339.

[13] Thouvenin L, Olivier T, Banna G, Addeo A, Friedlaender A. Immune checkpoint inhibitor-induced aseptic meningitis and encephalitis: a case-series and narrative review. Ther Adv Drug Saf. 2021;12:20420986211004745.

[14] Jarius S, Kleiter I, Ruprecht K, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: brainstem involvement—frequency, presentation and outcome. J Neuroinflammation. 2016;13(1):281.

[15] Wells G, Yuan H, McDaniel MJ, et al. The GluN2B-Glu413Gly NMDA receptor variant arising from a de novo GRIN2B mutation promotes ligand-unbinding and domain opening. Proteins Struct Funct Bioinf. 2018;86(12):1265-1276.

[16] Warikoo N, Brunwasser SJ, Benz A, et al. Positive allosteric modulation as a potential therapeutic strategy in anti-NMDA receptor encephalitis. J Neurosci. 2018;38(13):3218-3229.

[17] Hughes EG, Peng X, Gleichman AJ, et al. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci. 2010;30(17):5866-5875.

[18] Wenke NK, Kreye J, Andrzejak E, et al. N-methyl-D-aspartate receptor dysfunction by unmutated human antibodies against the NR1 subunit. Ann Neurol. 2019;85(5):771-776.

[19] Dao LM, Machule ML, Bacher P, et al. Decreased inflammatory cytokine production of antigen-specific CD4+T cells in NMDA receptor encephalitis. J Neurol. 2021;268(6):2123-2131.

[20] Schwenkenbecher P, Skripuletz T, Lange P, et al. Intrathecal antibody production against epstein-barr, herpes simplex, and other neurotropic viruses in autoimmune encephalitis. Neurol Neuroimmunol Neuroinflam. 2021;8(6):e1062.

[21] Ellul MA, Wood G, Tooren HVD, Easton A, Babu A, Michael BD. Update on the diagnosis and management of autoimmune encephalitis. Clin Med. 2020;20(4):389-392.

[22] Taraschenko O, Zimmerman EA, Bunch ME, McKee MA. Anti-NMDA receptor encephalitis associated with atrial fibrillation and hearing loss. Neurol Neuroimmunol Neuroinflam. 2014;1(3):e24.

[23] Corazzi V, Hatzopoulos S, Bianchini C, et al. The pathogenesis of secondary forms of autoimmune inner ear disease (AIED): advancing beyond the audiogram data. Expert Rev Clin Immunol. 2021;17(3):233-246.

[24] Goodall AF, Siddiq MA. Current understanding of the pathogenesis of autoimmune inner ear disease: a review. Clin Otolaryngol. 2015;40(5):412-419.

[25] Berti E, Vannucci G, Lunardi C, et al. Identification of autoantibodies against inner ear antigens in a cohort of children with idiopathic sensorineural hearing loss. Autoimmunity. 2013;46(8):525-530.

[26] Hervier B, Bordure P, Audrain M, Calais C, Masseau A, Hamidou M. Systematic screening for nonspecific autoantibodies in idiopathic sensorineural hearing loss: no association with steroid response. Otol Neurotol. 2010;31(4):687-690.

[27] Bonaguri C, Orsoni JG, Zavota L, et al. Anti-68 kDa antibodies in autoimmune sensorineural hearing loss: are these autoantibodies really a diagnostic tool. Autoimmunity. 2007;40(1):73-78.

[28] Tang X, Zhu X, Ding B, Walton JP, Frisina RD, Su J. Age-related hearing loss: GABA, nicotinic acetylcholine and NMDA receptor expression changes in spiral ganglion neurons of the mouse. Neuroscience. 2014;259:184-193.

[29] Bing D, Lee SC, Campanelli D, et al. Cochlear NMDA receptors as a therapeutic target of noise-induced tinnitus. Cell Physiol Biochem. 2015;35(5):1905-1923.

[30] Kaur C, Saini S, Pal I, et al. Age-related changes in the number of cresyl-violet-stained, parvalbumin and NMDAR 2B expressing neurons in the human spiral ganglion. Hear Res. 2020;388:107883.

[31] Hong J, Chen Y, Zhang Y, et al. N-methyl-D-aspartate receptors involvement in the gentamicin-induced hearing loss and pathological changes of ribbon synapse in the mouse cochlear inner hair cells. Neural Plast. 2018;2018:1-16.

[32] Usami S, Matsubara A, Fujita S, Shinkawa H, Hayashi M. NMDA (NMDAR1) and AMPA-type (GluR2/3) receptor subunits are expressed in the inner ear. Neuroreport. 1995;6(8):1161-1164.

[33] Dalmau J, Tüzün E, Wu H, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol. 2007;61(1):25-36.

RIGHTS & PERMISSIONS

2023 The Authors. Ibrain published by Affiliated Hospital of Zunyi Medical University (AHZMU) and Wiley-VCH GmbH.